Status:
COMPLETED
Rel. BA of Empagliflozin (BI 10773)/Linagliptin FDC Tbl, Comparison With Mono-components, With a Second FDC Tablet and Influence of Food
Lead Sponsor:
Boehringer Ingelheim
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The primary objective of the current study is to investigate the relative bioavailability of BI 10773 / linagliptin fixed dose combination tablet (formulation A1, Treatment A, Test) compared to BI 107...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- healthy male and female subjects
Exclusion
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
Estimated Enrollment :
42 Patients enrolled
Trial Details
Trial ID
NCT01189201
Start Date
August 1 2010
Last Update
March 19 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
1275.3.1 Boehringer Ingelheim Investigational Site
Biberach, Germany